Citations

Clear

511 citation(s) found for "Seth, N".

Variation in Lipid Management for Atherosclerotic Cardiovascular Disease Across US Health Systems
Shah, Nishant , Peterson, Eric D. , Shrader, Peter, Shoji, Satoshi , Freeman, Nikki , Martin, Seth S., Allred, Clint, Fernandez, S. A., Chamberlain, Alanna M., Arnold, Jonathan , Shapiro, Michael D., Priest, Elisa L. , Syed, Mahanaz, Kirchner, H. Lester , Leja, Monika, Kalich, Bethany , Jin, Ran , Navar, Ann Marie, Peterson, Eric D. , Chamberlain, Alanna M. , Arnold, Jonathan , Shah, Nishant P , Martin, Seth S , Fernandez, Soledad , Chamberlain, Alanna M , Shapiro, Michael D , Effron, Mark B , Syed, Mahanaz , Kirchner, H Lester , Kalich, Bethany , Jin, Ran , Wojcik, Cezary , Navar, Ann Marie , Shrader, Peter, Martin, Seth S. , Ahmad, Zahid , Jones, Laney K , Návar, Ann Marie

Mayo Clinic

Circulation: Population Health and Outcomes | February 20, 2026 | Volume: 19 | Issue: 4 | Pages: No page available

10.1161/circoutcomes.125.012622 | PMID 41717695 Get It

BACKGROUND: While health systems have implemented resources to improve lipid management in people with atherosclerotic cardiovascular disease, the population-level effectiveness is unclear. METHODS: Electronic health record data from patients with atherosclerotic cardiovascular disease between January 1, 2021, and December 31, 2023, across 16 US academic health systems were analyzed. Atherosclerotic cardiovascular disease (defined by diagnosis and procedure codes) was established on or before the index date defined as the date of the most recent LDL-C (low-density lipoprotein-cholesterol) or the last day of the study period for those without an LDL-C available. Systems were surveyed to identify lipid management programs (eg, prevention/lipid clinic, electronic health record–based tools, and lipid management algorithms). Sequential multilevel multivariable logistic regression modeling was used to (1) assess the system-level association between an LDL-C <70 mg/dL and the presence of lipid management programs, adjusting for patient-level demographic and clinical characteristics, and (2) whether system-level uptake of statin or nonstatin lipid-lowering therapy was associated with an LDL-C <70 mg/dL. RESULTS: We included 1 738 042 patients with atherosclerotic cardiovascular disease (median, 88 365 per system; range, 17 086–2 48 371). About 81% of the health systems had prevention or lipid clinics. The proportion of those on statins ranged from 31.0% to 60.4% across health systems (median, 46.3%). Lower proportions were observed in the use of high-intensity statins (16.2%–33.1%), nonstatins (2.6%–8.1%), and combination lipid-lowering therapy (1.7%–6.3%). Among those with an LDL-C level available (n=890 521), 42.5% had an LDL-C <70 mg/dL, ranging 35.8% to 49.4% across systems. There was no association between the odds of achieving LDL-C <70 mg/dL and health system lipid management algorithm, prevention clinics/lipid clinics, or electronic health record–based tools. Neither system-level high-intensity statin utilization nor nonstatin use was associated with an LDL-C <70 mg/dL. CONCLUSIONS: Despite variability in lipid management resources and lipid-lowering therapy use across systems, many did not reach an LDL-C <70 mg/dL, and there was low uptake of lipid-lowering therapy. Innovative implementation strategies are needed for system-level lipid management.
Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy
Singh, P., Singh, Parminder , Singh, Parminder , Lerner, Seth P.

Mayo Clinic

New England Journal of Medicine | February 18, 2026 | Volume: 394 | Issue: 13 | Pages: 1334-1336

10.1056/nejme2515777 | PMID 41707168 Get It

A novel approach to defining progression in MDS and precursor myeloid conditions in the MDS Natural History Study
DeZern, A. E., Otterstatter, Michael , Abel, Gregory A., Padron, Eric , Deeg, H. Joachim, Baghdadi, Tareq Al, Liu, Jane Jijun, Zhang, L, Kroft, Steven H. , Harrington, Alexandra M., Foran, J., Komrokji, Rami S., Starczynowski, Daniel T, Gore, Steven D, Saber, Wael, Bejar, Rafael, Lindsley, R. Coleman, Sherman, Seth, Lee, Cecilia , DiFronzo, Nancy, Sekeres, Mikkael A, Zhang, Ling , Gillis, Nancy , Otterstatter, Michael , Deeg, H Joachim , Zhang, Ling , Kroft, Steven H , Komrokji, Rami S , Bejar, Rafael , Lindsley, R Coleman , Sherman, Seth , Sekeres, Mikkael A , Baghdadi, Tareq Al , Dezern, Amy Elizabeth , Abel, Gregory A. , Deeg, H. Joachim , Xie, Zhuoer , Moscinski, Lynn C. , Foran, James M. , Komrokji, Rami S. , Starczynowski, Daniel T. , Gore, Steven D. , Saber, Wael , Walter, Matthew J , Sekeres, Mikkael A.

Mayo Clinic

Blood Advances | February 11, 2026 | Volume: 10 | Issue: 8 | Pages: 2743-2753

10.1182/bloodadvances.2025018770 | PMID 41671442 Get It

Abstract Patients at risk for progression from myeloid precursor states (idiopathic cytopenia of undetermined significance [ICUS] and clonal cytopenia of undetermined significance [CCUS]) to myelodysplastic syndrome (MDS) are not well defined. Epidemiologic risk factors, clonal changes for MDS development, and evolution from one MDS state to another were available in the MDS Natural History Study (NHS), a prospective cohort enrolled at diverse US sites. Extensive clinical data and biospecimens were collected at baseline and follow-up. A total of 1177 (56%) individuals with MDS or MDS-related precursor conditions (ICUS/idiopathic dysplasia of undetermined significance [IDUS], CCUS, and MDS/myeloproliferative neoplasm overlap) were enrolled and diagnosed in the MDS NHS. The median age was 74 years, with 89% aged ≥60 years, and most were male patients. Median follow-up time was 1.6 years and was similar among ICUS/IDUS, CCUS, and MDS. During follow-up period, 68% of participants terminated the study, 35% died, and 38% had disease progression. Using a refined clinical definition of progression, the greatest proportion of progression was observed among higher-risk-MDS (116 [73%]), followed by lower-risk-MDS (170 [52%]); fewer progression events were observed among participants with CCUS (65 [22%]) and ICUS/IDUS (46 [17%]). Predictors of progression are delineated, including female sex, higher quantity of mutations, the presence of TP53 mutation, and poor/very poor cytogenetic score. Based on these prospective data, guidelines for clinical management including monitoring and surveillance are outlined. The MDS NHS provides real-world data to illustrate how clinical and genotypic differences inform the classification, disease course, and approach to therapy, with informed monitoring guidelines for patients. This trial was registered at www.ClinicalTrials.gov as NCT02775383.
Artificial Intelligence for Gastroenterology Practice: A Modified Delphi Consensus
Gross, Seth, Shaukat, Aasma, Afzali, A, Ahn, Joseph C., Bajaj, Jasmohan S. , Barkin, Jodie A. , Bilal, Mohammad, Chawla, Saurabh , Coelho-Prabhu, Nayantara, Enslin, Sarah , Feld, Andrew, Gagneja, Harish K., Hass, David J., Horst, Sara N., Jones, Patricia D. , Kushnir, Vladimir M., Leggett, Cadman L. , Leung, Galen G., Mascarenhas, M., Parasa, Sravanthi, Parsa, Nasim , Schairer, Jason N., Spiegel, Brennan, Suthrum, Praveen, Thomas, Sapna, Phillips, Meridith E., Coelho–Prabhu, Nayantara , Spiegel, Brennan , Afzali, Anita , Ahn, Joseph , Bilal, Mohammad , Afzali, Anita , Ahn, Joseph C , Coelho-Prabhu, Nayantara , Enslin, Sarah M , Hernandez-Barco, Yasmin G , Horst, Sara , Jacobson, Brian C , Jones, Patricia D , Kaul, Vivek , Leggett, Cadman L , Leung, Galen , Mascarenhas, Miguel , Parasa, Sravanthi , Shah, Eric D , Simonetto, Douglas A , Stidham, Ryan W , Suthrum, Praveen , Thomas, Sapna , Phillips, Meridith E , Bilal, Mohammad , Spiegel, Brennan , Shaukat, Aasma , Afzali, Arya , Feld, Andrew D., Hernandez‐Barco, Yasmin G. , Horst, Sara , Kushnir, Vladimir , Parasa, Sravanthi , Schairer, Jason, Shah, Eric D. , Simonetto, Douglas A.

Mayo Clinic

American Journal of Gastroenterology | February 10, 2026 | Volume: 121 | Issue: 4 | Pages: 1017-1024

10.14309/ajg.0000000000003944 | PMID 41665234 Get It

INTRODUCTION: The American College of Gastroenterology assembled a multidisciplinary task force to evaluate the current state and future direction of artificial intelligence (AI) in gastroenterology, hepatology, and endoscopy leading to the development of consensus-based recommendations for responsible AI integration in clinical practice. METHODS: A total of 32 subject-matter experts and 12 industry partners, representing diverse practice settings and expertise, conducted subgroup literature reviews across 5 key areas (endoscopy, practice management clinical applications, training and education, inflammatory bowel disease and liver disease, ethics and equity). Draft statements were developed and rated on a 5-point Likert scale using a modified Delphi process. A consensus was set at ≥70% combined agreement. Nonconsensus items were revised and revoted electronically. RESULTS: A total of 43 statements, 40 (93%) reached consensus in round 1 and the remaining 3 achieved consensus after round 2. Evidence supports computer-aided detection improving adenoma detection rate and miss rate in controlled studies, with mixed real-world impact and insufficient long-term outcomes (e.g., interval colon cancer rate). Recommendations emphasize thorough validation and reduction of bias by heterogeneous Data sets. Outside endoscopy, ambient AI scribes, natural language processing (NLP)-enabled coding, workflow optimization, and previous authorization support show potential. Training recommendations endorse a structured AI curriculum while preserving independent procedural competence to avoid deskilling. In inflammatory bowel disease and hepatology, AI could help improve diagnostic accuracy, help predict risk of disease progression, and help guide therapy. Equity, governance, and reimbursement statements call for chain-of-custody data protections, specialty-society oversight, and payment models that reward quality and cost reduction. DISCUSSION: This consensus outlines how AI can augment rather than replace clinical expertise while promoting safety, transparency, interoperability, and equity. Priorities include pragmatic and prospective trials, multi-institutional data-sharing consortia, bias mitigation, and workforce training to enable trustworthy and clinically impactful AI adoption in gastroenterology, liver, and endoscopy care.
The Sport Publication Observational Research Tool (SPORT): An Objective Tool to Score the Methodological Quality of Observational Clinical Sports Medicine Research
Kuhn, Andrew W. , Inclan, Paul M. , Haider, Ameer A. , Christy, Michele, Dunn, Warren, Alberton, Laura A. , Allen, Christina, Anderson, Kyle, Andrews, James, Azar, Fred, Baer, Geoffrey S. , Banffy, Michael B. , Bedi, Asheesh , Brockmeier, Stephen F., Brophy, Robert H. , Bush‐Joseph, Charles A., Carey, James R. , Carter, Thomas, Cohen, Steven, Farrow, Lutul D. , Flanigan, D. Preston, Franklin, Corinna C. , Hame, Sharon L. , Ioannis, Terzidis, Joseph, Sheeba, Kenter, Keith , Koh, Jason R., Krych, Aaron, LeClere, LT Lance, Levy, Bruce, McAllister, David, Morganti, Christina, Musahl, Volker , Nelson, Bradley , Noyes, Frank, Owens, COL Brett D., Pace, Lee, Paulos, Lonnie E., Rodeo, Scott, Safran, Marc, Savoie, Felix H. , Shelbourne, Donald K., Sherman, Seth L. , Singer, Ken, Smith, Matthew, Sonnery-Cottet, Bertrand, Spiker, Andrea M. , Stuart, Michael, Warren, Russell, Wittstein, Jocelyn R. , Wolcott, Michelle L., Wright, Rick, Matava, Matthew J. , Sherman, Seth L. , Kuhn, Andrew W , Dunn, Warren R., Brockmeier, Stephen F. , Brophy, Robert H. , Carey, James, Cohen, Steven B. , Flanigan, David, Krych, Aaron J. , LeClere, Lance E. , Lee, Cassandra Alda , Levy, Bruce, McAllister, David R. , Medvecky, Michael J. , Owens, Brett D. , Pace, J Lee , Redler, Lauren H. , Rodeo, Scott A. , Sonnery‐Cottet, Bertrand

Mayo Clinic

Orthopaedic Journal of Sports Medicine | February 6, 2026 | Volume: 14 | Issue: 2 | Pages: No page available

10.1177/23259671251380883 | PMID 41660291 Get It

Background: A critical component of conducting systematic reviews or meta-analyses is assessing the methodological quality and bias of included studies. Several methodological quality assessment tools have been developed; however, these tools may not be relevant to observational sports medicine research, which carries numerous unique nuances and biases. Purpose: To develop the Sport Publication Observational Research Tool (SPORT), which evaluates and scores the methodological quality of observational sports medicine research. Study Design: Consensus statement. Methods: SPORT was developed through a modified Delphi approach involving members from the Herodicus Society and The FORUM. All active members were invited to participate in the process aimed at building consensus on SPORT content and scoring. After finalizing SPORT, a power analysis led to the independent selection of 55 observational clinical sports medicine studies, which were scored twice by 4 reviewers of varying training levels. Interrater and intrarater reliability for SPORT was assessed using intraclass correlation coefficients (ICCs). The distribution and percentiles for total SPORT score across the 55 studies were calculated. SPORT was also compared with the methodological index for non-randomized studies (MINORS), a commonly utilized quality assessment tool. Results: A total of 51 members participated and achieved 100%, 100%, 98.0%, and 98.0% completion rates for rounds 1 through 4, respectively. The final SPORT included 19 subscores related to methodological quality and bias and achieved 94% consensus approval. Mean SPORT completion time was 6 minutes and 19 seconds per study, which varied significantly by reviewer training level. The subscore "peer review" demonstrated unacceptable reliability and was removed. The remaining 18 subscores exhibited ICC ranges of 0.599 to 0.955 for interrater reliability and 0.530 to 0.936 for intrarater reliability. Total SPORT score demonstrated excellent agreement, for interrater (ICC, 0.967) and intrarater reliability (ICC, 0.966). Median SPORT score across the 55 studies was 20.0 and skewed toward lower scores. There was a moderate significant correlation between SPORT and MINORS ( r [53] = 0.575; P < .001). Conclusion: An objective tool to assess the methodologic quality of observational sports medicine research (SPORT) was successfully developed through a modified Delphi approach with numerous content experts in the field. This tool may be useful in assessing the methodological quality of primary observational sports medicine studies included in systematic reviews and meta-analyses.
Safety and Feasibility of Concomitant Urogynecologic and Gynecologic Oncology Surgical Procedures
Wohlrab, Kyle, Robison, Katina, Rahn, David D. , Dunivan, Gena C., Occhino, John, Pennycuff, Jon, Frimer, Marina, Lokich, Elizabeth, Ring, Kari, Uyar, Denise , Winer, Ira, Richter, Holly E., Wohlrab, Kyle J., Robison, Katina M. , Occhino, John A. , Pennycuff, Jon F., Frimer, Marina , Ring, Kari Lassen , Winer, Ira Seth , Richter, Holly E

Mayo Clinic

Urogynecology | January 27, 2026 | Volume: 32 | Issue: 2 | Pages: 76-89

10.1097/spv.0000000000001804 | PMID 41589867 Get It

This joint Clinical Consensus Statement on the safety and feasibility of concomitant urogynecologic and gynecologic oncology surgical procedures reflects statements drafted by content experts from the American Urogynecologic Society and the Society of Gynecologic Oncology. The writing group used a Delphi process to evaluate statements developed from a structured literature search and assessed consensus. A total of 35 statements were assessed in the following categories: (1) background, (2) treatment options, (3) timing of concurrent surgery, (4) risk factors, and (5) value-based care. Of the 35 statements, 28 reached consensus on initial review. Three statements were omitted, and 4 statements were revised and reached consensus following second review utilizing the Delphi process.
MedMatch: a first step for the automation of large language model performance benchmarking for medication-related tasks
Blotske, Kaitlin , Zhao, Xingmeng , Cargile, Moriah , Tilley, Adeleine , Murray, Brian, Gao, Yanjun, Henry, Kelli , Smith, Susan E, Barreto, Erin, Bauer, Seth R. , Sohn, Sunghwan , Liu, Tianming, Smith, Susan , Murray, Brian , Henry, Kelli , Gao, Yanjun , Murray, Brian , Gao, Yanjun , Smith, Susan E , Frazee, Erin N , Bauer, Seth R , Liu, Tianming , Sikora, Andrea , Frazee, Erin N. , Blotske, Kaitlin , Zhao, Xingmeng

Mayo Clinic

No container title available | January 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.01.13.26343949 | PMID 41646690 Get It

Abstract Background The accuracy and safety of generating medication orders by large language models (LLMs) must be demonstrated. Without standardization, performance evaluation is limited to time and resource-intensive clinician grading. This evaluation aimed to develop a standardized medication format that supports automated performance evaluation (MedMatch). Methods First, a survey of 40 medication prompts was given to clinicians to assess agreement in medication order communication. Second, a clinician panel developed a standardized medication format (MedMatch) for oral and intravenous medications. Third, a clinician-annotated dataset of medication prompts and standardized answers in the MedMatch format was developed for LLM testing. Finally, LLMs were retested with the same dataset, adjusted to exclude route information, to evaluate the appropriate categorization of medication route. Results The formal medication orders consistently showed low omission rates and high overlap for all entities, compared to the verbal and brief written communication types. Lexical overlap results demonstrated pattern norms amongst clinicians with entities appearing most commonly in positions 1-5 in the order of drug name, dose, unit, route, and frequency. In the second survey, the formal written group performed the highest with 78.3% of prompts considered appropriate as a computer-generated response. LLM accuracy on MedMatch order standardization was highest in oral solid (64.2-72.5%), intravenous intermittent (72.5-84.3%), and intravenous push (62.7-74.5%) categories. LLMs performed the worst at categorizing medication orders accurately into intravenous push (18-61%) and intravenous intermittent (51-100%) routes. Conclusions Standardized format for computer-based outputs may support automated performance analysis and enhance the clarity of medication communication.
Drug or Pokémon? Large language model performance in identification of fabricated medications
Henry, Kelli , Murray, Brian, Zhao, Xingmeng , Blotske, Kaitlin , Gao, Yanjun, Smith, Brooke, Smith, Susan , Barreto, Erin, Bauer, Seth R. , Sohn, Sunghwan , Liu, Tianming , Cohen, Mitch, Abdulnour, Raja-Elie E, Le, Khoa , Zhou, Hongjian , Clifton, David A. , Murray, Brian , Henry, Kelli , Gao, Yanjun , Smith, Brooke , Murray, Brian , Gao, Yanjun , Smith, Susan E , Frazee, Erin N , Bauer, Seth R , Bennett, Tell , Cohen, Mitch , Abdulnour, Raja-Elie E , Sikora, Andrea , Sohn, Sunghwan , Frazee, Erin N. , Celi, Leo Anthony , Liu, Fenglin , Blotske, Kaitlin , Zhao, Xingmeng

Mayo Clinic

No container title available | January 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.01.12.26343930 | PMID 41646757 Get It

Abstract Background Large language models (LLMs) are increasingly used in medication-related tasks despite limited evidence supporting their accuracy and safety. LLMs are vulnerable to adversarial attacks and may confabulate in response to fabricated information in the prompt. Given the substantial risk of harm from medication errors, the purpose of this study was to establish a benchmark task to evaluate LLM performance in distinguishing fabricated from real medications. Methods Two datasets (brand and generic), each consisting of 250 medication lists were developed, each including 4-6 medications and one fabricated medication (specifically a Pokémon character), with complete dosing information provided. Six LLMs were evaluated (GPT-5-Chat, GPT-4o-mini, DrugGPT, Gemma-3-27B-IT, Llama-3.3-70B-Instruct, and Qwen3-32B). For each medication list, models were queried for dosing information and disease indication across three experimental conditions: standard decoding, standard decoding with mitigation prompting, and deterministic decoding (temperature = 0). Each experiment was performed in triplicate. Outputs were deemed confabulations if the LLM failed to recognize and reject the fabricated medication. The primary outcome was the rate of confabulations. Exact paired-permutation tests were used to compare confabulation rates across LLMs and prompting approaches. Results Confabulation rates under standard conditions ranged from 2.7% to 99.6%. DrugGPT demonstrated the lowest baseline confabulation rates (2.7-6.4%), whereas other models demonstrated substantially higher rates (47.2-99.6%). Mitigation prompting significantly reduced confabulation rates compared to standard and deterministic decoding across all tasks and datasets (p < 0.001): GPT-5-Chat achieved confabulation rates of 0% with mitigation prompting from baseline rates of 66.4-88.5%. Deterministic decoding did not substantially impact confabulation rates. Conclusions LLMs performing medication-related tasks are susceptible to confabulation in response to invalid or fabricated inputs, raising important safety concerns for clinical use. While mitigation prompting reduced confabulation rates, this study underscores the importance of robust safeguards when deploying LLMs in medication-related decision-making.
Outcomes After Colon Conduit Urinary Diversion: A Multi-Institutional Retrospective Study From the Reconstruction and Diversion: Improving Outcomes Group
Hebert, Kevin , Swinney, Seth , Johnson, Ryan, Ramsay, Joemy M. , Fendereski, Kiarad , DeWitt-Foy, Molly , Bearrick, Elizabeth , Maymi-Castrodad, Patricia, Stoffel, John T. , Seyer, A, McCormick, Benjamin J. , Myers, JeremyB, Hebert, Kevin J , Ramsay, Joemy , Bearrick, Elizabeth , Maymi-Castrodad, Patricia , Stoffel, John T , Seyer, Amanda, Viers, Boyd R , McCormick, Benjamin J , Myers, Jeremy B , Elliott, Sean, Viers, Boyd R.

Mayo Clinic

Journal of Urology | January 13, 2026 | Volume: 215 | Issue: 5 | Pages: 621-632

10.1097/ju.0000000000004935 | PMID 41529173 Get It

Validation of Methylated DNA Markers for Esophageal Squamous Cancer: An International Study
Matchett, Caroline L. , Wf, Taylor, Chalmers, Collin E., Foote, Patrick H. , Berger, Calise K. , Mulima, Gift , Tomoka, Tamiwe , Khan, Shiraz, Mahoney, Douglas W. , Albert, Paul S. , Abnet, Christian C., Dawsey, Sanford M., Chen, Yingxi, Iyer, Prasad G. , Slettedahl, Seth W , Taylor, William R , Chalmers, Collin E , Foote, Patrick H , Berger, Calise K , Mulima, Gift , Tomoka, Tamiwe , Khan, Shiraz , Mahoney, Douglas W , Albert, Paul S , Abnet, Christian C , Dawsey, Sanford M. , Chen, Yingxi , Kisiel, John B , Iyer, P G , Slettedahl, Seth W. , Abnet, Christian C. , Kisiel, John B.

Mayo Clinic

Cancer Prevention Research | January 13, 2026 | Volume: 19 | Issue: 4 | Pages: 197-201

10.1158/1940-6207.capr-25-0383 | PMID 41527379 Get It

Abstract Esophageal squamous cell carcinoma (ESCC) remains a leading cause of cancer-related mortality worldwide, and there are limited molecular screening options. Following a prior discovery and validation studies in subjects from the United States, China, and Iran, we aimed to validate methylated DNA markers (MDM) for ESCC detection in Malawi, a country with one of the highest ESCC incidence. Fourteen MDMs were tested on 177 tissue samples. Ten MDMs showed excellent performance (AUCs ≥ 0.85); a random forest model achieved an AUC of 0.97. The consistent cross-population performance suggests potential for universal application of these MDMs and further justifies exploring nonendoscopic sampling methods, such as swallowed cell collection devices in combination with MDMs, for efficient and cost-effective screening in high-incidence populations. Prevention Relevance: This study validates MDMs for early detection of ESCC in Malawi, supporting their potential role in noninvasive, population-based screening strategies in Africa to enable early detection and timely intervention for cancer interception, potentially reducing cancer burden in high-incidence, resource-limited regions.